Cladribine

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2936 publications

Treatment of Erdheim-Chester disease from the perspective in 2026.

Treatment of Erdheim-Chester disease from the perspective in 2026.

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti
Published: August 28, 2026

Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model.

Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model.

Journal: Health technology assessment (Winchester, England)
Published: August 11, 2026

Long-term efficacy of cladribine tablets: Results from the MAGNIFY-MS Extension study.

Long-term efficacy of cladribine tablets: Results from the MAGNIFY-MS Extension study.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: August 04, 2026

Langerhans cell histiocytosis in the adult lower gastrointestinal tract.

Langerhans cell histiocytosis in the adult lower gastrointestinal tract.

Journal: BMJ case reports
Published: July 21, 2026

The Art of Sequencing Disease-Modifying Therapies in Multiple Sclerosis.

The Art of Sequencing Disease-Modifying Therapies in Multiple Sclerosis.

Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: July 16, 2026

From options to decisions: an innovative model for treatment sequencing in relapsing-remitting multiple sclerosis.

From options to decisions: an innovative model for treatment sequencing in relapsing-remitting multiple sclerosis.

Journal: Journal of medical economics
Published: June 24, 2026

Differences in the imaging of Erdheim-Chester disease using FDG-PET/CT, NaF-PET/CT examinations, and skeletal scintigraphy. Regression of the disease after treatment with cladribine combined with cyclophosphamide and anakinra.

Differences in the imaging of Erdheim-Chester disease using FDG-PET/CT, NaF-PET/CT examinations, and skeletal scintigraphy. Regression of the disease after treatment with cladribine combined with cyclophosphamide and anakinra.

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti
Published: June 22, 2026

French expert opinion on the long-term management of relapsing multiple sclerosis with cladribine tablets beyond year 4.

French expert opinion on the long-term management of relapsing multiple sclerosis with cladribine tablets beyond year 4.

Journal: Journal of neurology
Published: June 15, 2026

Real-world treatment and outcomes in hairy cell leukemia: a multicenter retrospective cohort including BRAF inhibitor therapy.

Real-world treatment and outcomes in hairy cell leukemia: a multicenter retrospective cohort including BRAF inhibitor therapy.

Journal: Leukemia & lymphoma
Published: June 12, 2026

Cladribine-based salvage therapy in relapsed/refractory AML: A multicenter retrospective study.

Cladribine-based salvage therapy in relapsed/refractory AML: A multicenter retrospective study.

Journal: Leukemia research
Published: June 07, 2026

From Clinical Trial Efficacy to Real-World Effectiveness and Safety: Two-Year Outcomes of Cladribine in Relapsing-Remitting Multiple Sclerosis.

From Clinical Trial Efficacy to Real-World Effectiveness and Safety: Two-Year Outcomes of Cladribine in Relapsing-Remitting Multiple Sclerosis.

Journal: Journal of clinical medicine
Published: June 06, 2026

Correction: Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two‑year Phase IV CLARIFY‑MS Study.

Correction: Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two‑year Phase IV CLARIFY‑MS Study.

Journal: Neurology and therapy
Published: June 01, 2026
Showing 1-12 of 2,936

Last Updated: 09/26/2026